



Express Mail Mailing Label No. EV926974370US

PATENT
Attorney Docket No. WYE-031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Martinez *et al.* CONFIRMATION NO.: 2977
SERIAL NO.: 10/751,736 GROUP NO.: 1642
FILING DATE: January 6, 2004 EXAMINER: Yao, Lei
TITLE: Compositions and Methods for Diagnosing and Treating Colon Cancers

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) above but before the mailing date of any of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
 - the requisite Statement is below, **OR**
 - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or

Supplemental Information Disclosure Statement

Serial No.: 10/751,736

Page 2 of 2

- (3) after the period defined in (2) above but before the payment of the **issue fee**, **AND**
 the requisite Statement is below, **AND**
 the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Brian A. Fairchild, Ph.D.
Attorney for Applicants
Kirkpatrick & Lockhart Preston
Gates Ellis LLP
State Street Financial Center
One Lincoln Street
Boston, Massachusetts 02111-2950

Date: January 10, 2007
Reg. No. 48,645

Tel. No.: (617) 261-3169
Fax No.: (617) 261-3175

BOS-1043537 v1



Express Mail Mailing Label No. EV926974370US

SHEET 1 OF 1

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: WYE-031 APPLICANT(S): Martinez, et al. SERIAL NO.: 10/751,736 FILING DATE: January 6, 2004 GROUP NO.: 1642					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	A1	US 2004/0005313A1	01/08/2004	Clevers <i>et al.</i>				07/16/2002	
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	WO 2004/005457 A2	01/15/2004	WO			07/08/2003	N	Y
	B2	WO 2004/040828 A2	05/13/2004	WO			10/30/2003	N	Y
	B3	WO 2004/074436 A2	09/02/2004	WO			02/11/2004	N	Y
	B4	WO 2004/098521 A2	11/18/2004	WO			04/28/2004	N	Y
	B5	EP 1 602 930 A2	12/07/2005	EP			08/20/2004	N	N
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
C1	European Search Report dated March 17, 2006, 7 pages.								
C2	McClanahan <i>et al.</i> , "Identification of Overexpression of Orphan G Protein-Coupled Receptor GPR49 in Human Colon and Ovarian Primary Tumors," <i>Cancer Biology & Therapy</i> , 5(4):419-426, April 2006.								
C3	Yamamoto <i>et al.</i> , "Overexpression of Orphan G-Protein-Coupled Receptor, <i>Gpr49</i> , in Human Hepatocellular Carcinomas with β -Catenin Mutations," <i>Hepatology</i> , 37(3):528-533, March 2003.								
EXAMINER				DATE CONSIDERED					